Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

14.37 +0.86 (+6.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
7 Analysts Have This to Say About Arcutis Biotherapeutics
Via Benzinga
8 Analysts Have This to Say About Arcutis Biotherapeutics
Via Benzinga
Analyst Ratings for Arcutis Biotherapeutics
Via Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
Via Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
Arcutis Appoints Interim Chief Financial Officer (CFO)
Former and First Arcutis CFO, John Smither, Appointed Interim 
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Arcutis Biotherapeutics
Via Benzinga
Arcutis Biotherapeutics: Q1 Earnings Insights
Via Benzinga
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report Second Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Where Arcutis Biotherapeutics Stands With Analysts
Via Benzinga
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Shares of Arcutis Biotherapeutics Jumped This Week
The stock got a push when a British medical journal posted trials information on the company's lead product. 
Via The Motley Fool
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
7 Short-Interest Stocks to Target for Explosive Gains
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report First Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.